9VQ Stock Overview
Develops and commercialize oxygen related medical device products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Belluscura plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.10 |
| 52 Week High | UK£0.28 |
| 52 Week Low | UK£0.08 |
| Beta | 1.14 |
| 1 Month Change | -9.91% |
| 3 Month Change | -21.88% |
| 1 Year Change | -56.14% |
| 3 Year Change | -92.00% |
| 5 Year Change | n/a |
| Change since IPO | -83.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9VQ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.7% | -3.0% | -2.6% |
| 1Y | -56.1% | -7.8% | 7.1% |
Return vs Industry: 9VQ underperformed the German Medical Equipment industry which returned -6.9% over the past year.
Return vs Market: 9VQ underperformed the German Market which returned 8% over the past year.
Price Volatility
| 9VQ volatility | |
|---|---|
| 9VQ Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 9VQ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 9VQ's weekly volatility has decreased from 16% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 35 | Bob Rauker | www.belluscura.com |
Belluscura plc develops and commercialize oxygen related medical device products in the United States. The company offers X-PLOR and DISCOV-R, a modular portable oxygen concentrator; and related accessories. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.
Belluscura plc Fundamentals Summary
| 9VQ fundamental statistics | |
|---|---|
| Market cap | €18.79m |
| Earnings (TTM) | -€17.94m |
| Revenue (TTM) | €1.74m |
10.8x
P/S Ratio-1.0x
P/E RatioIs 9VQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9VQ income statement (TTM) | |
|---|---|
| Revenue | US$1.80m |
| Cost of Revenue | US$5.37m |
| Gross Profit | -US$3.57m |
| Other Expenses | US$15.04m |
| Earnings | -US$18.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | -197.53% |
| Net Profit Margin | -1,030.73% |
| Debt/Equity Ratio | 0% |
How did 9VQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 22:38 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Belluscura plc is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Richards | Dowgate Capital Stockbrokers Limited |
| David Joseph Storms | Stonegate Capital Markets, Inc. |
| David Joseph Storms | Stonegate Capital Partners, Inc. |